- Details
- Description
Nivorest 100 (Nivolumab 100 mg/10 mL) is an antineoplastic immunotherapy containing nivolumab, a monoclonal antibody that blocks the PD-1 immune checkpoint, helping the immune system recognize and attack cancer cells. It is supplied as a 10 mg/mL concentrate for intravenous infusion, with each 10 mL vial containing 100 mg of nivolumab.
It is used, alone or in combination with other anticancer medicines, for several cancers including melanoma, non-small-cell lung cancer, renal cell carcinoma, head and neck cancer, and certain esophageal, gastric, and colorectal cancers, depending on the approved indication and patient characteristics.
Important: Nivolumab can cause serious immune-mediated adverse reactions affecting organs such as the lungs, liver, intestines, kidneys, skin, and endocrine glands, so it must be administered under specialist medical supervision.
